Trademark: 79345827
Word
YAVEMBO
Status Date
Tuesday, January 23, 2024
Registration Number
7282283
Registration Date
Tuesday, January 23, 2024
Filing Date
Wednesday, April 27, 2022
Published for Opposition
Tuesday, November 7, 2023
5 Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone
10 Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
Jul 21, 2022
Sn Assigned For Sect 66a Appl From Ib
Jul 22, 2022
New Application Office Supplied Data Entered
Jul 26, 2022
Application Filing Receipt Mailed
Feb 15, 2023
Assigned To Examiner
Feb 16, 2023
Non-Final Action Written
Feb 17, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Apr 5, 2023
Refusal Processed By Mpu
Apr 5, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Apr 25, 2023
Refusal Processed By Ib
Jul 24, 2023
New Representative At Ib Received
Oct 2, 2023
Teas Response To Office Action Received
Oct 2, 2023
Correspondence Received In Law Office
Oct 3, 2023
Teas/Email Correspondence Entered
Oct 4, 2023
Approved For Pub - Principal Register
Oct 18, 2023
Notification Of Possible Opposition Sent To Ib
Oct 18, 2023
Notification Of Notice Of Publication E-Mailed
Oct 18, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Nov 6, 2023
Notification Processed By Ib
Nov 7, 2023
Published For Opposition
Nov 7, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 27, 2023
Notification Of Possible Opposition Sent To Ib
Dec 27, 2023
Notification Of Possible Opposition Created, To Be Sent To Ib
Jan 23, 2024
Registered-Principal Register
Jan 13, 2024
Notification Of Possible Opposition - Processed By Ib
Jan 23, 2024
Notice Of Registration Confirmation Emailed
Apr 24, 2024
Final Disposition Notice Sent To Ib
Apr 24, 2024
Final Disposition Processed
May 13, 2024
Final Decision Transaction Processed By Ib
Apr 23, 2024
Final Disposition Notice Created, To Be Sent To Ib
Trademark Alertz updated from USPTO on 2030-01-24
